Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses
Viruses · 2025
DOI: 10.3390/v17091165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Alessandro Pardini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza A Virus, H1N1 Subtype, Orthomyxoviridae Infections, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation.
Abstract (Originalsprache)
Influenza remains a major health threat due to its high contagiousness and global spread, affecting not only humans but also agricultural livestock and wild animals through transmission via migratory birds. Despite over 70 years of vaccination, influenza still creates epidemics and pandemics, and the ongoing use of vaccination is an essential but currently insufficient strategy. In this study, we assessed the immunogenicity and efficacy of an AP205 virus-like particle (VLP) carrying the HA head domain of the A/PR8/H1N1 strain, administered intranasally and subcutaneously in mice. For this purpose, the entire head region of A/PR8/H1N1 was genetically integrated into a sterically improved version of AP205, which exhibits capsid monomers fused into a dimer, thereby offering inexpensive and scalable production processes. The vaccine induced strong systemic anti-HA IgG and IgA antibodies via both routes, with no significant difference in the levels of IgG. Both immunisation strategies induced protection against a lethal challenge with H1PR8 mouse-adapted influenza virus. The findings demonstrate the potential of the AP205 VLP platform for HA1-based influenza vaccines and its applicability for controlling influenza in both humans and livestock.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of BioMedical Research, University of Bern, 3008 Bern, Switzerland.
- Department of Rheumatology and Immunology, University Hospital Bern, 3008 Bern, Switzerland.
- Graduate School of Cellular and Biomedical Sciences, University of Bern, 3008 Bern, Switzerland.
- International Immunology Centre, Anhui Agricultural University, Hefei 230036, China.
- Latvian Biomedical Research & Study Centre, Ratsupites iela 1, LV 1067 Riga, Latvia.
- Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
ORCID-Profile: Alessandro Pardini, Pascal S Krenger, Monique Vogel, Martin F Bachmann
Förderung
- Swiss National Science Foundation
Zitieren
APA
Pardini, A., Rothen, D. A., Krenger, P. S., Vogt, A. C., Josi, R., Liu, X., Tars, K., Kopf, M., Vogel, M., & Bachmann, M. F. (2025). Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses. Viruses. https://doi.org/10.3390/v17091165
Vancouver
Pardini A, Rothen DA, Krenger PS, Vogt AC, Josi R, Liu X, et al. Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses. Viruses. 2025. doi:10.3390/v17091165
BibTeX
@article{Pardini2025,
author = {Pardini, Alessandro and Rothen, Dominik A and Krenger, Pascal S and Vogt, Anne-Cathrine and Josi, Romano and Liu, Xuelan and Tars, Kaspars and Kopf, Manfred and Vogel, Monique and Bachmann, Martin F},
title = {Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17091165}
}
EUVIMED